GLP-1 in CF Modulator Era: New Obesity Considerations

Cystic fibrosis used to be a disease of nutritional failure. Pancreatic enzyme insufficiency, chronic lung infection, and elevated resting energy expenditure meant CF dietitians spent decades pushing calorie density and a target BMI ≥ 22 in women and ≥ 23 in men. Then Trikafta (elexacaftor- tezacaftor-ivacaftor) arrived in 2019 (Middleton NEJM^[1]), survival began climbing, and the historic undernutrition reversed. Petersen 2022^[2] reported an average BMI gain of roughly +1.1 kg/m² in the first year on Trikafta in adults, and Ratti 2025^[3] documented new metabolic syndrome in roughly a quarter of patients at the 12-month mark. The adult CF clinic now sees a problem nobody planned for: obesity, in patients who still have pancreatic exocrine insufficiency, still take dozens of pills daily, and still carry CF-related diabetes risk. This article walks through what the published GLP-1 in CF literature actually says, where the drug-interaction landscape sits, and the practical pulmonology / CF-center consultation pathway.

The honest summary

• The Trikafta era reversed CF undernutrition. Petersen 2022 (J Cyst Fibros^[2]) reported mean BMI gains of ~+1.1 kg/m² in the first year on elexacaftor-tezacaftor-ivacaftor (ETI); the Alicandro 2026 24-month real-world cohort^[5] confirmed sustained weight gain with a meaningful share of adults crossing into the overweight or obese range.
• About one in four ETI-treated adults develops metabolic syndrome by year one. Ratti 2025^[3] followed adult CF patients prospectively and documented new dyslipidemia, hypertension, and insulin resistance — a clinical phenotype that did not exist in the pre-modulator CF clinic.
• GLP-1 in CF data is thin and is mostly case-level. Kumar 2026 (Respirology Case Reports^[8]) is one of the first published case reports of a woman with CF and obesity treated with a GLP-1 receptor agonist; the report also flags muscle dysfunction and bone-density loss as worth tracking in this population. There are no CF-specific RCTs.
• The mechanism is preserved. The L-cell incretin axis sits in the distal small intestine and is not CFTR-dependent, so GLP-1 receptor agonist pharmacology in CF mirrors the non-CF obesity setting. The variables that change in CF are concurrent pancreatic enzyme replacement therapy (PERT), fat-soluble vitamin status, and the lung-function endpoint that matters most.

How the Trikafta era created an obesity problem in CF

Before 2019, CF dietitians fought daily for weight. Resting energy expenditure ran 10–30% above predicted, fat malabsorption from pancreatic exocrine insufficiency was the rule, and chronic Pseudomonas-driven inflammation consumed calories. The Cystic Fibrosis Foundation nutrition guidelines targeted a BMI ≥ 22 in adult women and ≥ 23 in adult men because lung function tracks with BMI in CF.

Middleton 2019 (NEJM^[1]) reported a 13.8-point absolute improvement in percent-predicted FEV1 with elexacaftor-tezacaftor-ivacaftor in patients with a single Phe508del allele — the largest single-drug FEV1 improvement ever reported in CF. CFTR restoration also reduces resting energy expenditure, improves intestinal absorption, and reduces inflammatory cytokine load. Petersen 2022^[2] followed adults on ETI and documented an average BMI gain of ~+1.1 kg/m² in the first year, with a meaningful proportion crossing into BMI ≥ 25.

Alicandro 2026 (Nutrition^[5]) extended this to a 24-month real-world cohort and confirmed that weight gain does not plateau quickly. Ratti 2025 (J Cyst Fibros^[3]) followed a separate adult cohort and reported new metabolic syndrome — the combination of central adiposity, dyslipidemia, hypertension, and impaired glucose tolerance — in roughly a quarter of patients at one year on ETI. Girouard 2026 (European Respiratory Review^[6]) systematically reviewed cardiometabolic outcomes across 18+ ETI cohort studies and confirmed a consistent signal: triglycerides up, LDL up, blood pressure up, fasting insulin up.

Solis-Garcia 2024 (Nutrients^[4]) framed the clinical question directly — “Is Obesity a Problem in New Cystic Fibrosis Treatments?” — and concluded that the historic high-fat, high-calorie CF diet is no longer universally appropriate. Linguiti 2026 (Biology^[7]) made the same point under a “Beyond BMI” framing: the modern CF nutrition target needs to weight body composition, lean mass, and bone density — not raw BMI.

What “~23% overweight” actually means

The figure cited at the top of this article — about 23% of adult CF patients now overweight or obese — pulls from the Cystic Fibrosis Foundation Patient Registry and from the Alicandro^[5] and Petersen^[2] longitudinal cohorts. The number used to be single-digit. The directional message across all of the cited cohorts is consistent: BMI distribution in adult CF has shifted to the right by roughly one full kg/m² cohort-wide since ETI uptake, and the right tail (BMI ≥ 30) is no longer empty.

The GLP-1 in CF evidence: case-level, signal-positive

Kumar 2026 (Respirology Case Reports^[8]) is one of the few formally published GLP-1-in-CF reports. The case describes a woman with CF and obesity treated with a GLP-1 receptor agonist for weight loss; the authors report meaningful weight reduction but also flag two CF-specific concerns — reduced muscle strength and reduced bone-mineral density — that the broader sarcopenic-obesity literature has flagged across non-CF populations as well. The takeaway is not that GLP-1 is unsafe in CF; it is that CF patients enter weight loss with a baseline lean-mass and bone-density disadvantage and need a lean-mass-preservation protocol baked into the prescription from day one. See our companion piece on muscle-loss prevention for the protein and resistance- training scaffolding that protects lean mass on a GLP-1.

There are no GLP-1 RCTs in CF. The evidence base is case reports, case series, and pharmacologic plausibility arguments. The incretin axis is anatomically downstream of the CFTR defect — L-cells release native GLP-1 in response to nutrient sensing in the distal small intestine and colon, and this pathway is not impaired by CFTR dysfunction. Exogenous GLP-1 receptor agonists therefore work via the same receptor and the same downstream signaling cascade in CF as in non-CF patients.

CFTR modulator pharmacokinetics and GLP-1: no documented interaction

Ivacaftor, tezacaftor, and elexacaftor are all CYP3A4 substrates — their plasma concentrations rise with strong CYP3A4 inhibitors (clarithromycin, ketoconazole) and fall with strong inducers (rifampin, St. John's wort). GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are peptides, not small molecules. They are not CYP3A4 substrates, not CYP3A4 inhibitors, and not CYP3A4 inducers. There is no documented pharmacokinetic interaction between any GLP-1 receptor agonist and any CFTR modulator.

Two practical caveats apply. First, GLP-1 receptor agonists slow gastric emptying. This can affect the Cmax of co-administered oral drugs taken with the same meal. ETI is dosed with a fat-containing meal to support absorption, and slowed gastric emptying could in principle extend the absorption window. We are not aware of a published case of clinically meaningful ETI exposure change attributable to a GLP-1, but a CF center clinical pharmacist should be in the loop on initiation. Second, oral semaglutide (Rybelsus) requires a 30-minute pre-meal fasting window with minimal water — that is incompatible with the with-fat ETI dosing instruction and we recommend injectable GLP-1 formulations in CF.

Pancreatic enzyme replacement therapy on a GLP-1

Roughly 85% of people with CF have pancreatic exocrine insufficiency and take PERT (Creon, Pancreaze, Zenpep, Pertzye, or Viokace) with every meal and snack. PERT contains lipase, amylase, and protease, dosed by lipase units per gram of dietary fat. There is no documented interaction between PERT and GLP-1 receptor agonists. Patients should continue PERT exactly as prescribed: with every meal and snack, dosed to fat intake. The reduced food intake on a GLP-1 will reduce total daily PERT capsule count proportionally, but the per-meal dose ratio does not change.

Cystic fibrosis-related diabetes and the GLP-1 question

Cystic fibrosis-related diabetes (CFRD) affects roughly 20% of adolescents and up to ~50% of adults with CF. The pathophysiology is dominantly insulin deficiency from progressive pancreatic islet destruction, with a smaller insulin-resistance component. Historic guidelines (Moheet 2018, Lurquin 2023^[9]) recommended insulin as the first-line treatment for CFRD because endogenous insulin production is the rate-limiting step and because the historic CF patient was undernourished, not insulin- resistant.

The Trikafta era is shifting that picture. Adults on ETI who are overweight or obese with new-onset CFRD now look more like a type 2 diabetes phenotype than a classical CFRD phenotype — insulin resistance is meaningful, endogenous insulin production is partially preserved, and the obesity is the dominant glycemic driver. The Lurquin 2023^[9] review explicitly raised the question of whether non-insulin agents (including GLP-1 receptor agonists) deserve a role in CFRD management in the modulator era. The published RCT base is still absent, but the physiologic case for a GLP-1 in an overweight ETI-treated adult with mixed CFRD / type-2-like diabetes is reasonable — managed jointly by CF endocrinology.

Magnitude: BMI trajectory in CF by treatment era

The practical protocol

1. BMI > 30 in an adult on ETI is a reasonable GLP-1 candidate. The published evidence does not support a CF-specific contraindication, but CF center coordination is non-negotiable. Pulmonology, CF dietitian, and the prescribing obesity medicine clinician all need to be in the loop.
2. Start low, titrate slow. CF gastrointestinal motility runs slow at baseline — pancreatic insufficiency, distal intestinal obstruction syndrome (DIOS) risk, and chronic constipation are common. Standard semaglutide or tirzepatide titration may produce more nausea and DIOS risk than in non-CF patients. The 0.25 mg semaglutide starting dose held for an extended 4–6 weeks before stepping up is reasonable.
3. Continue PERT exactly as prescribed. Dose to fat content per meal. Reduced meal volume on a GLP-1 will reduce total daily capsule count proportionally.
4. Monitor what matters in CF. BMI trend, FEV1 (lung function) every 3 months, lean mass via DEXA at baseline and 12 months, fat-soluble vitamin levels (A, D, E, K) at 6 and 12 months, CFRD glucose monitoring per local CF center protocol, and HbA1c at 3 and 6 months.
5. Avoid in pediatric CF. The published adult evidence does not extend to children; pediatric CF patients still need calorie density to support growth and lung function.
6. Coordinate with the lung transplant team if relevant. CF patients on the transplant list, or post-transplant, have additional considerations around immunosuppression, weight optimization, and pre-listing BMI targets that sit outside the scope of this article.

Insurance and cost considerations

CF patients in the United States have unusually robust insurance access: state Medicaid programs, the Cystic Fibrosis Foundation Compass program, and CF-center social work teams collectively close most coverage gaps. The CFTR modulator cost (Trikafta wholesale ~$322,000 per year) is generally covered without patient cost-sharing through patient assistance programs and orphan-drug pathways. A GLP-1 receptor agonist for obesity in a CF patient on Medicaid is typically subject to the same prior- authorization criteria as any other obesity indication; commercial coverage will vary by plan. The CF social work team is usually the fastest path to a coverage decision.

Related research

• GLP-1 for asthma and COPD — pulmonary outcomes on GLP-1 receptor agonists in obesity-related lung disease
• GLP-1 muscle-loss prevention protocol — the protein and resistance-training scaffolding that protects lean mass during weight loss, especially relevant given the Kumar 2026 case-report flags
• GLP-1 first 30 days survival guide — titration nausea and GI management, doubly relevant in CF where baseline GI motility runs slow
• GLP-1 and history of pancreatitis — relevant given chronic pancreatic disease in CF

Important disclaimer. This article is educational and does not constitute medical advice. Cystic fibrosis is a complex multi-system disease and any addition of a GLP-1 receptor agonist to a CF regimen must be coordinated with the patient's accredited CF center. The published GLP-1-in-CF evidence is case-level; there are no CF-specific randomized controlled trials at the time of writing. CFTR modulator and GLP-1 receptor agonist pharmacokinetics do not have documented interactions, but slowed gastric emptying may affect the absorption of co-administered oral medications and CF center clinical pharmacy consultation is recommended. Pediatric CF patients are not addressed by this article. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if a CF-specific GLP-1 trial reads out.